Actavis launches generic version of Opana ER

Branded version's manufacturer sues Actavis, alleging patent infringement

PARSIPPANY, N.J. — Actavis has launched a generic version of an extended-release opioid painkiller, the company said.

The drug maker announced the launch of oxymorphone extended-release tablets in the 5-mg, 10-mg, 20-mg, 30-mg and 40-mg strengths. Actavis received approval for the drug in July.

The drug is a generic version of Endo's Opana ER. Endo is currently suing Actavis, alleging that Actavis' generic infringes some of its patents. The drug is used for around-the-clock pain relief.

According to IMS Health, Opana ER tablets had sales of about $461 million during the 12-month period that ended in May. Actavis already markets the 7.5-mg and 15-mg strengths of the drug.


Login or Register to post a comment.